Markets:

Overview

News

Currencies

International

Treasuries

Verona Pharma plc - American Depositary Shares (NQ:VRNA)

106.91 UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 6, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Verona Pharma plc - American Depositary Shares

< Previous 1 2 3 4 5 Next >

Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today ↗

June 05, 2025

Via The Motley Fool

Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data ↗

May 30, 2025

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal.

Via Benzinga

Jim Cramer Says This Quantum Computing Stock Is 'So High' And 'Too Speculative' ↗

May 28, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

May 27, 2025

Via Benzinga

Earnings Scheduled For April 29, 2025 ↗

April 29, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Earnings Scheduled For February 29, 2024 ↗

February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Via Benzinga

Earnings Preview For Verona Pharma ↗

February 28, 2024

Via Benzinga

Expert Ratings for Verona Pharma ↗

September 01, 2023

Via Benzinga

Earnings Scheduled For August 3, 2023 ↗

August 03, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 01, 2025

Via Benzinga

Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Week ↗

January 16, 2025

The company is working to launch its COPD treatment more broadly. The drug is a non-steroidal nebulizer.

Via Investor's Business Daily

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent ↗

September 27, 2024

The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD.

Via Investor's Business Daily

Petco, AppLovin, Dave & Buster's And Other Big Stocks Moving Higher On Wednesday ↗

September 11, 2024

Via Benzinga

GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug ↗

September 06, 2024

GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary endpoint, reducing exacerbations significantly over 104 weeks.

Via Benzinga

Top 3 Health Care Stocks That May Crash In August ↗

August 14, 2024

Via Benzinga

9 Health Care Stocks Whale Activity In Today's Session ↗

August 13, 2024

Via Benzinga

VRNA Stock Earnings: Verona Pharma Misses EPS for Q2 2024 ↗

August 08, 2024

VRNA stock results show that Verona Pharma missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Top 3 Health Care Stocks You May Want To Dump This Quarter ↗

July 30, 2024

Via Benzinga

First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product ↗

June 27, 2024

The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

June 25, 2024

Via Benzinga

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More ↗

June 24, 2024

Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.

Via Benzinga

Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday ↗

June 13, 2024

Via Benzinga

Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks ↗

June 13, 2024

The companies are closing in on the finish line for two new COPD treatments.

Via Investor's Business Daily

VRNA Stock Earnings: Verona Pharma Misses EPS for Q1 2024 ↗

May 09, 2024

VRNA stock results show that Verona Pharma missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

3 Healthcare Stocks That Have Outperformed Nvidia Since 2022 ↗

March 01, 2024

The healthcare sector is no slouch when it comes to top-performing growth stocks.

Via The Motley Fool

3 Stocks That Could Be Monster Winners in 2024 ↗

December 30, 2023

Don't be surprised if these three stocks take off in the new year.

Via The Motley Fool

Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves ↗

December 29, 2023

In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK) Chief Commercial Officer Luke Miels revealed the company's intent to pursue acquisitions within the $2 billion...

Via Benzinga

Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

December 26, 2023

Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth...

Via Benzinga

Earnings Scheduled For November 2, 2023 ↗

November 02, 2023

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.